Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Overview of attention for article published in BMC Cancer, November 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 24 publications that cite this research output.

24

The most recent citing publications are shown below. View all 24 publications that cite this research output on Dimensions.

Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE)

Article in Journal of Thoracic Oncology (January 2024)

Photoinduced Ring Opening of Methyl 1-Aryl-5-oxo-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazole-2-carboxylates in the Presence of Diaryl Disulfides

Article in Molbank (June 2023)

Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond

Article in World Journal of Gastroenterology (March 2023)